# Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

Study · id `cardio:ct-nct01898221` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01898221](<https://clinicaltrials.gov/study/NCT01898221>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01898221

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 343 participants.

## Technical summary

Registry record NCT01898221. Randomized; single masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2019-12 (actual). Results posted on 2025-08-21.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 343 participants (enrolled count; ClinicalTrials.gov record NCT01898221, source copy `cardio:ctgov-nct01898221-2025-08-21`, retrieved 2026-10-26)
- Started: 2013-10 (actual) (ClinicalTrials.gov record NCT01898221, source copy `cardio:ctgov-nct01898221-2025-08-21`, retrieved 2026-10-26)
- Primary completion: 2019-12 (actual) (ClinicalTrials.gov record NCT01898221, source copy `cardio:ctgov-nct01898221-2025-08-21`, retrieved 2026-10-26)
- Completion: 2019-12 (actual) (ClinicalTrials.gov record NCT01898221, source copy `cardio:ctgov-nct01898221-2025-08-21`, retrieved 2026-10-26)
- Results first posted: 2025-08-21 (ClinicalTrials.gov record NCT01898221, source copy `cardio:ctgov-nct01898221-2025-08-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01898221, source copy `cardio:ctgov-nct01898221-2025-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01898221-2025-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
- Acronym: VOM-R01
- Condition: Ventricular Tachycardia
- Condition: Atrial Fibrillation
- Intervention (Drug): Ethanol
- Intervention (Procedure): Ablation
- Lead sponsor: The Methodist Hospital Research Institute
- Lead sponsor class: OTHER
- Collaborator: National Institutes of Health (NIH)
- Collaborator class: NIH
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: The Methodist Hospital Research Institute (`cardio:org-the-methodist-hospital-research-institute`)
- Registry lists this organization as a collaborator: National Institutes of Health (`cardio:nih`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial (`cardio:pubmed-33107945`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c6ce1d7c4d0067ea36455d23b9474ff72a0318955169d6ab1fc4c4ac0d87a9a3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
